EPISODE · Jan 25, 2024 · 31 MIN
291: The plight of the VC, Gilead's latest setback, & more M&A
from The Readout Loud · host STAT
We discuss how biotech's downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. We also take a look at Gilead Sciences' struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm. Subscribe to our biotech newsletter, The Readout.
Embed this episode
NOW PLAYING
291: The plight of the VC, Gilead's latest setback, & more M&A
0:00
31:15
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of The Readout Loud?
This episode is 31 minutes long.
When was this The Readout Loud episode published?
This episode was published on January 25, 2024.
Can I download this The Readout Loud episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!